Abstract: The present invention relates to methods and kits for the diagnosis, prognosis and/or monitoring of cancer in a patient. The present invention further relates to isolated peptides, panels of isolated peptides and diagnostic devices.

Abstract: The present invention relates to methods and kits for the diagnosis, prognosis and/or monitoring of cancer in a patient. The present invention further relates to isolated peptides, panels of isolated peptides and diagnostic devices.

Abstract: The present invention relates to a method for the early diagnosis of neoplastic disorders such as cancers as well as their precursor stages, particularly cancers of the respiratory tract, the urinary system, the reproductive tract, cancer associated with HPV infection or cancer of the anogenital tract, from solubilized body samples. The invention is also directed to test kits usable for this purpose as well as in-vitro diagnostic devices. The development of the kits and in-vitro diagnostic devices for the above purpose is also one aspect of the present invention.

Abstract: The present invention relates to nucleic acids and polypeptides associated with lung cancer. The invention is more specifically related to a nucleic acids and the polypeptides transcribed thereof, the expression of which is significantly altered in association with lung cancer. The invention relates to a series of differentially spliced transcripts of the gene disclosed herein, that are associated with tumors of the respiratory tract. Furthermore the present invention provides a method for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as e.g. lung tumors.

Abstract: The present invention relates to nucleic acids and polypeptides associated with lung cancer. The invention is more specifically related to a nucleic acids and the polypeptides transcribed thereof, the expression of which is significantly altered in association with lung cancer. The invention relates to a series of differentially spliced transcripts of the gene disclosed herein, that are associated with tumors of the respiratory tract. Furthermore the present invention provides a method for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as e.g. lung tumors.

Abstract: The present invention discloses the differential expression of the gene coding for F-box and leucine-rich repeat protein FBL2 in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, the invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for an F-box and leucine-rich repeat protein, in particular FBL2. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention relates to a method for the early diagnosis of neoplastic disorders such as cancers as well as their precursor stages, particularly cancers of the respiratory tract, the urinary system, the reproductive tract, cancer associated with HPV infection or cancer of the anogenital tract, from solubilized body samples. The invention is also directed to test kits usable for this purpose as well as in-vitro diagnostic devices. The development of the kits and in-vitro diagnostic devices for the above purpose is also one aspect of the present invention.

Abstract: The present invention discloses the differential expression of a gene coding for Ensadin-0138 in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the Ensadin-0138 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of the gene coding for the voltage-gated ion channel SCN2A in specific brain regions of Alzheimers disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer s disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer s disease and related neurodegenerative disorders using the voltage-gated ion channel gene SCN2A and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses a novel nucleic acid molecule encoding hTARPP. Further, the present invention discloses the differential expression of hTARPP in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the gene coding for hTARPP. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of the activator protein for vesicle secretion CAPS gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for an activator protein for vesicle secretion, in particular the CAPS gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention relates to nucleic acids and polypeptides associated with lung cancer. The invention is more specifically related to a nucleic acids and the polypeptides transcribed thereof, the expression of which is significantly altered in association with lung cancer. The invention relates to a series of differentially spliced transcripts of the gene disclosed herein, that are associated with tumors of the respiratory tract. Furthermore the present invention provides a method for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as e.g. lung tumors.

Abstract: The present invention discloses the differential expression of the onconeuronal antigen Ma2 gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for an onconeuronal antigen, in particular Ma2 onconeuronal antigen. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of the gene coding for F-box and leucine-rich repeat protein FBL2 in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, the invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for an F-box and leucine-rich repeat protein, in particular FBL2. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of the gene coding for the nuclear restricted protein/brain, NRP/B, in specific brain regions of Alzheimer's disease patients. Based on this finding this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for a nuclear restricted protein, in particular the nuclear restricted protein/brain, NRP/B. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of the caveolae-associated integral membrane protein flotillin-1 gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosing Alzheimer's disease or other neurodegenerative diseases in a patient, or for determining whether a subject is at increased risk of developing Alzheimer's disease or other related neurodegenerative diseases. Furthermore, this invention provides therapeutic and prophylatic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a caveolae-associated integral membrane protein gene, in particular the flotillin-1 gene. A method of screening for modulating agents of neurodegenerative, diseases is also disclosed.